Trump signs order to research psychedelic used abroad to treat PTSD
Summary
President Donald Trump signed an executive order to support research on the psychedelic drug ibogaine, which is used abroad to treat post-traumatic stress disorder (PTSD). The order includes a $50 million investment and efforts to ease restrictions, aiming to help patients, especially veterans, and allow quicker drug review by the FDA.Key Facts
- President Trump signed an order to promote research on ibogaine, a psychedelic drug.
- Ibogaine is used in some countries to treat PTSD, depression, anxiety, addiction, and brain trauma.
- The government will invest $50 million in researching ibogaine.
- The FDA will help speed up drug reviews by adding some psychedelics to a priority program.
- Ibogaine can be given to seriously ill patients under the FDA’s Right To Try rule.
- Ibogaine is currently a Schedule I drug, categorized with heroin and ecstasy, making it illegal in the U.S.
- The drug has risks, including dangerous heart rhythm problems that have caused deaths.
- More large, controlled studies are needed to prove ibogaine’s safety and effectiveness.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
